ONS ONCC Chemo Renewal exam:
Questions With 100% Complete
Solutions 2025|2026 Latest Update
Mrs. Turner's initial MUGA scan result was 55% and is now decreased to
48% which is a > 10% decrease in her LVEF. Per the prescribing
information for Perjeta, if the LVEF is 45%, or is 45% to 49% with a 10%
or greater absolute decrease below the pretreatment value, withhold
PERJETA and trastuzumab and repeat LVEF assessment within
approximately 3 weeks
(http://www.gene.com/download/pdf/perjeta_prescribing.pdf). You
should call the doctor to provide the results of the MUGA scan
compared to her initial MUGA scan and anticipate that the trastuzumab
and pertuzumab will be held for this cycle of chemotherapy. Mrs.
Turner should have a repeat MUGA scan prior to cycle #4 and based on
those results, discontinue PERJETA and trastuzumab if the LVEF has not
improved or has declined further, unless the benefits for the individual
patient outweigh the risks. - correct answer-You realize that since Mrs.
Turner is on a regimen that includes pertuzumab that she should have
her LVEF monitored every 6 weeks since she is receiving neoadjuvant
therapy. You review Mrs. Turner's most recent MUGA scan and see that
her LVEF is 48%.
,heart function - correct answer-Two of the agents in the patients
currecnt regimen, trastuzumab and pertuzumab, have the potential to
cause a decline in _____________
8.4% - correct answer-It is important that the nurse recognizes certain
drugs that, when given together, may result in a higher risk of adverse
events. For example, in neoadjuvant clinical trials using trastuzumab
and pertuzumab, the incidence of decline in left ventricular ejection
fraction (LVEF) was 1.9% in patients treated with trastuzumab and
docetaxel, compared to ______ of those treated with trastuzumab,
docetaxel, and pertuzumab (Genentech, 2013).
Consider the potential toxicity related to each drug.
Understand the monitoring guidelines for each drug.
Have knowledge of clinically significant signs and symptoms. - correct
answer-Key Points for Combination Therapy
Improved patient outcomes.
Increased nurse satisfaction.
Potential cost savings. - correct answer-Evidence-based practice can
have positive effects, such as:
, Smoking
Increased age
Alcohol intake
History of Polyps - correct answer-Risk factors for colon cancer
50 - correct answer-The chance of developing colorectal cancer
increases markedly after age _____. Roughly 9 out of 10 people
diagnosed with colorectal cancer are at least ____ years old.
Racial and ethnic backgrounds (African Americans and Jews of Eastern
European descent (Ashkenazi Jews) have highest incidence)
Diet high in red and processed meats
Physical inactivity, obesity
Type 2 diabetes
Family history of colon cancer or inflammatory bowel disease
Inherited familial syndromes (FAP, HNPCC) - correct answer-Other risk
factors for the development of colorectal cancer include:
Questions With 100% Complete
Solutions 2025|2026 Latest Update
Mrs. Turner's initial MUGA scan result was 55% and is now decreased to
48% which is a > 10% decrease in her LVEF. Per the prescribing
information for Perjeta, if the LVEF is 45%, or is 45% to 49% with a 10%
or greater absolute decrease below the pretreatment value, withhold
PERJETA and trastuzumab and repeat LVEF assessment within
approximately 3 weeks
(http://www.gene.com/download/pdf/perjeta_prescribing.pdf). You
should call the doctor to provide the results of the MUGA scan
compared to her initial MUGA scan and anticipate that the trastuzumab
and pertuzumab will be held for this cycle of chemotherapy. Mrs.
Turner should have a repeat MUGA scan prior to cycle #4 and based on
those results, discontinue PERJETA and trastuzumab if the LVEF has not
improved or has declined further, unless the benefits for the individual
patient outweigh the risks. - correct answer-You realize that since Mrs.
Turner is on a regimen that includes pertuzumab that she should have
her LVEF monitored every 6 weeks since she is receiving neoadjuvant
therapy. You review Mrs. Turner's most recent MUGA scan and see that
her LVEF is 48%.
,heart function - correct answer-Two of the agents in the patients
currecnt regimen, trastuzumab and pertuzumab, have the potential to
cause a decline in _____________
8.4% - correct answer-It is important that the nurse recognizes certain
drugs that, when given together, may result in a higher risk of adverse
events. For example, in neoadjuvant clinical trials using trastuzumab
and pertuzumab, the incidence of decline in left ventricular ejection
fraction (LVEF) was 1.9% in patients treated with trastuzumab and
docetaxel, compared to ______ of those treated with trastuzumab,
docetaxel, and pertuzumab (Genentech, 2013).
Consider the potential toxicity related to each drug.
Understand the monitoring guidelines for each drug.
Have knowledge of clinically significant signs and symptoms. - correct
answer-Key Points for Combination Therapy
Improved patient outcomes.
Increased nurse satisfaction.
Potential cost savings. - correct answer-Evidence-based practice can
have positive effects, such as:
, Smoking
Increased age
Alcohol intake
History of Polyps - correct answer-Risk factors for colon cancer
50 - correct answer-The chance of developing colorectal cancer
increases markedly after age _____. Roughly 9 out of 10 people
diagnosed with colorectal cancer are at least ____ years old.
Racial and ethnic backgrounds (African Americans and Jews of Eastern
European descent (Ashkenazi Jews) have highest incidence)
Diet high in red and processed meats
Physical inactivity, obesity
Type 2 diabetes
Family history of colon cancer or inflammatory bowel disease
Inherited familial syndromes (FAP, HNPCC) - correct answer-Other risk
factors for the development of colorectal cancer include:
